retatrutide clinical trial duration Eli Lilly infiltrates anti-obesity market as Phase III for begins When does the first phase

Taming the Tummy Troubles: Eating to Minimize Side Effects One of the most discussed aspects of GLP-1 therapy is the potential for gastrointestinal (GI) side effects

This study is expected to conclude in late 2025, providing critical data on CagriSemas potential as a superior weight loss treatment

GLP-1 receptors arent just found in the pancreas and brain

In the 12 mg arm, participants achieved a mean body weight reduction of approximately 24% at 48 weeks the highest observed across the dose groups though this arm was also associated with a higher incidence of gastrointestinal side effects

But while the future is bright, the present is powerful

Injection sites should be rotated with each weekly dose to prevent lipohypertrophy and ensure consistent drug absorption